| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7070581 | AZURITY | Dispenser for medicaments and method and apparatus for making same |
Jun, 2023
(9 months ago) | |
| US8517997 | AZURITY | Dispenser for medicaments and method and apparatus for making same |
May, 2024
(23 days from now) | |
| US10576070 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(13 years from now) | |
| US11207306 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(13 years from now) | |
| US11806338 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(13 years from now) | |
| US11413277 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(13 years from now) | |
| US11517563 | AZURITY | Liquid nimodipine compositions |
Apr, 2038
(13 years from now) | |
| US11759457 | AZURITY | Liquid nimodipine compositions |
Apr, 2038
(13 years from now) | |
| US10342787 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(13 years from now) | |
Nymalize is owned by Azurity.
Nymalize contains Nimodipine.
Nymalize has a total of 9 drug patents out of which 1 drug patent has expired.
Expired drug patents of Nymalize are:
- US7070581
Nymalize was authorised for market use on 10 May, 2013.
Nymalize is available in solution;oral dosage forms.
Nymalize can be used as a method for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry aneurysms.
The generics of Nymalize are possible to be released after 16 April, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-46) | May 10, 2020 |
| Orphan Drug Exclusivity(ODE) | May 10, 2020 |
Drugs and Companies using NIMODIPINE ingredient
Market Authorisation Date: 10 May, 2013
Treatment: A method for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry a...
Dosage: SOLUTION;ORAL
NYMALIZE family patents
